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ABSTRACT 
Synthesis of a new Scytovirin Protein Derivative, SD1-SD2-SD2, to Decrease HIV-1 Binding 
Affinity to Human Cells 
 
 Scytovirin is a novel anti-viral protein isolated from the cyanobacterium Scytonema 
varium. This protein has produced great scientific interest for its anti-human immunodeficiency 
virus (HIV) activity. Scytovirin disrupts the mechanism of HV infection by binding to HIV-1 
proteins glycoprotein 120, glycoprotein 160, and glycoprotein 41. It does not bind to the CD4 
receptor on human immune cells. The wild-type protein consists of a single 95 amino acid chain. 
When folded, Scytovirin’s amino acid sequence is arranged into two distinct domains, each with a 
high degree of sequence conservation. This implicates the importance of both domains in anti-
HIV activity.   
 Primers were designed and constructed to synthesize three novel, mutant, forms of the 
Scytovirin protein in an attempt to increase the anti-HIV activity of Scytovirin. Each gene analog 
featured coding to increase the size of the new mutant proteins by the addition of the second 
domain onto the nearly wild-type protein. The amino acid sequence connecting this domain was 
unique to each mutant. Single amino acids were replaced at numerous locations in each domain 
through site-directed mutagenesis to facilitate proper folding of the proteins. Once the gene 
constructs were sequenced and purified, all three mutants were expressed in Escheria coli, each 
with thrombin (THR) fused to its N-terminus. The protein constructs, three versions of SD1-SD2-
SD2, were cleaved from THR with restriction enterokinase (rEK). Soluble protein was purified 
using polyhistidine tag affinity purification through FPLC, and HPLC. NMR determined the 
structures of the proteins and if proper folding had occurred.
iv	  
	  
SD1-SD2-SD2 wild-type and short linkers were expressed in Origami cells, purified, and 
examined by 2D Heteronuclear NOESY NMR. NMR of SD1-SD2-SD2 wild-type linker 
indicated that the protein had not folded completely. Additional research involving the expression 
and purification parameters of SD1-SD2-SD2 is required to obtain proper folding before SD1-
SD2-SD2 will be screened against HIV-1 to assess anti-viral activity.  
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LIST OF ABBREVIATIONS 
APS  Ammonium persulfate 
C  Cysteine 
CD4                 Receptor HIV-1 binds on human cells 
CB  Carbenicillin 
CM  Chloramphenocol 
CXCR4 Chemokine receptor 4 
DEPC  Diethylpyrocarbonate 
DTT  Dithiothreitol 
EDTA  Ethylenediaminetetraacetic acid 
ELISA              Enzyme-linked immune sorbent assay 
Env                   Envelope glycoprotein  
FPLC  Fast protein liquid chromatography (Nickel Column) 
gp41               Glycoprotein 41 
gp120             Glycoprotein 120 
gp160             Glycoprotein 160 
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HPLC            High performance liquid chromatography 
HR1             heptad repeat 1 region of gp41 
HR2                  heptad repeat 2 region of gp41 
IPTG  Isopropylthiogalactoside 
JM109  E. coli cell line 
KO  Knock-out (deleted gene) 
LB  Luria-Bertani broth 
LL  Long linker 
M9  Minimal Media number 9 
MES  2-(N-morpholino)ethanesulfonic acid 
NaN3  Sodium azide 
NF-κB             Nuclear factor kappa-light-chain-enhancer of activated B cells 
NMR  Nuclear magnetic resonance 
NOESY Nuclear Overhauser Effect Spectroscopy 
OD  Optical density 
PCR  Polymerase chain reaction 
PMSF  phenylmethanesulfonylfluoride 
rEK  Restriction enterokinase 
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S  Serine 
SD1  Scytovirin Domain 1 
SD2  Scytovirin Domain 2 
SDS  Sodium dodecyl sulfate 
SIV  Simian immunodeficiency virus 
SL  Short linker 
TEMED Tetramethylethylenediamine 
THR  Thrombin 
TFA  Trifluoroacetic acid 
WT  Wild-type 
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I.  INTRODUCTION 
Human immunodeficiency virus type-1 (HIV-1) is a retrovirus which acts by infecting the 
CD4 (cluster of differentiation 4) positive T-lymphocytes (T-cells) and macrophages of the 
human immune system. Infection with the HIV-1 virus results in the progressive deterioration and 
impairment of the host immune system, leading to ‘immune deficiency’. CD4 positive cells form 
the basis of cell-mediated immunity in humans, comprising T-lymphocytes and macrophages. 
Viral destruction of these cells leaves the host susceptible to opportunistic infections and cancers, 
most of which are rarely seen in healthy individuals. Progressive damage to the immune system 
by HIV-1 and other opportunistic infections eventually leads to acquired immunodeficiency 
syndrome (AIDS) and death. (Schacker, et al) 
HIV is thought to have originated from crossing of simian immunodeficiency virus (SIV) 
from chimpanzees into humans sometime in the early 20th century in western Africa (Keele, et 
al). The spread of HIV-1 was initially slow, but spread rapidly worldwide due to rapid 
urbanization. HIV-1 infection was first recognized by medical publications of advanced immune 
deficiency, later termed AIDS, in the 1980s. Unusual cases of Kaposi’s sarcoma, a rare form of 
relatively benign cancer affecting the elderly, among young, previously healthy individuals were 
reported in large U.S. cities in 1981. The high incidence of this new condition in homosexual men 
caused the CDC to name the disease gay-related immunodeficiency (GRID). However, cases 
reported in heterosexuals in December of 1981 caused scientists to rethink the at-risk population. 
In 1983, cases were reported in Europe, Uganda, Australia, Canada, Latin America and Japan. 
Later that year, Luc Montangier and Francoise Barre-Sinoussi isolated the suspected virus. In 
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1984, Robert Gallo confirmed that the causative agent was a retrovirus, which was given the 
name human immunodeficiency virus. (Barre-Sinoussi, et al)  
Transmission of HIV-1 from an infected individual to an uninfected individual occurs by 
entrance of infected bodily fluids; semen, vaginal fluids, blood or breast milk, entrance into the 
uninfected individual’s body. The most common modes of infection are unprotected sexual 
intercourse, injection drug use, and from infected mother to infant during delivery or breast-
feeding. Blood transfusions and organ transplants were an initial source of HIV-1 spreading; 
however, with advanced tests and screenings the risk of infection from these procedures is 
extremely low. (Kaiser) 
Infection with HIV-1 initiates a four-stage, lengthy disease that ultimately results in death by 
an opportunistic infection taking advantage of the crippled immune system. The first phase of 
HIV-1 infection is marked by an asymptomatic incubation period, which is the reason that most 
people do not know that they have become infected. A small number of people develop acute 
retroviral syndrome at the time of seroconversion, the production of antibodies to HIV-1, 1-6 
weeks after the initial infection. (Schacker, et al) Retroviral syndrome is characterized by fever, 
malaise, pharyngitis, diarrhea, generalized lymphadenopathy, and rash. This complex of 
symptoms is easily confused with other illnesses such as infectious mononucleosis or influenza; 
which explains why most people do not learn of their illness until the disease enters the later 
stages. 
During acute primary infection, plasma HIV-1 RNA concentrations can be very high, making 
the risk of secondary transmission to uninfected individuals extremely high. After the symptoms 
of primary infection diminish, the infected individual enters the second phase of HIV-1, the 
asymptomatic latent phase. This stage can persist for several years, averaging 8 to 10, but rapid 
progression through this stage is usually common. During this stage, HIV is actively replicating 
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and continuing to weaken the immune system. The symptomatic disease phase, progressing for 
one to three years, emerges as the peripheral CD4 positive cell count falls below 350 cells per µL 
of blood. As white blood cell counts continue to fall, many infected individuals become 
susceptible to infections and exhibit HIV-1 disease-related symptoms. The final stage of infection 
is marked by the progression of HIV-1 to AIDS, when the immune system’s ability to fight 
infections unassisted is compromised. A diagnosis of AIDS is given when a patient’s white blood 
cell count falls below 200 cells per µL of blood and patients experience multiple opportunistic 
infections. (Schacker, et al) 
 
Figure 1.1 Diagram depicting the structure and essential proteins of HIV-1. Reprinted with permission from Dr. Robert 
McFeeters (personal correspondence). 
HIV-1 is spherical in shape, has a diameter of 1/10,000 of a millimeter, and is constructed of 
a protein capsid surrounded by an outer envelope composed of two layers of fatty acids, taken 
from the membrane of the human cell from which it assembled. Embedded within the viral 
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envelope are proteins from the host cell membrane as well as approximately 72 copies of the 
complex protein Envelope Glycoprotein (Env). Env is a conical structure consisting of a cap 
composed of three molecules of glycoprotein 120 (gp120), and a stem of three molecules of 
glycoprotein 41 (gp41) that anchors the structure into the viral envelope. (De Clerq) HIV-1 
infection of macrophages and CD4 
positive T-cells is mediated through the 
interaction of the viral envelope 
glycoproteins 120 and 41(gp120, gp41) 
with the CD4 molecule on the target cells. 
(Mondor, et al) CD4 is an integral 
membrane glycoprotein, belonging to the 
immunoglobin gene family, which is 
expressed mainly on the surface of T-cells 
and the cells of the macrophage/monocyte 
lineage. 
Adsorption begins when Env interacts 
nonspecifically with heparin sulfate, a 
sulfated polysaccharide that is involved in 
adsorption of many enveloped viruses and 
is widely expressed in animal cells. This 
initial interaction provides the opportunity 
for other copies of Env to interact with 
CD4. Once the virus has attached to the 
CD4 receptor, the viral Env gp120 interacts 
with its co-receptor, chemokine receptor 4 (CXCR4). This interaction triggers shape changes in 
Figure 1.2: Life cycle of HIV-1. (Reprinted with permission 
from Nature: open content file) 
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the gp120-gp41 complex that ultimately changes the secondary structure of gp41. The more 
stable, double-pronged attachment allows the N-terminal fusion peptide gp41 to penetrate the 
host cell membrane. (Wyatt, Sodrowski) Interaction of repeat sequences in gp41, HR1 and HR2 
causes the collapse of the extracellular portion of gp41 into a hairpin structure. This fuses the 
viral envelope with the membrane of the target cell, and the viral capsid, containing viral RNA 
and essential viral protein, is injected into the cell. (De Clerq) 
Once inside the host cell, the viral capsid is uncoated, thought to be accomplished by 
phosphorylation of the protein matrix surrounding the capsid. Uncoating produces the reverse 
transcription complex, containing primers and various proteins necessary for transcription. 
(Cartier, et al) Then, reverse transcriptase transcribes the single-stranded RNA genome of HIV-1 
into double-stranded DNA, which is then incorporated into the host’s genome by the viral 
enzyme integrase. The integrated viral DNA may remain unexpressed for some time, allowing the 
virus to escape detection by the immune system. Certain transcription factors are necessary for 
the expression of the viral genes including NF-κB, which is upregulated when the T-cells are 
currently fighting infection. Therefore, the most active T-cells, the ones fighting the infection, 
will be the ones to express the viral genes and assemble more virus particles to spread the 
infection. (Kaiser)  
Since its discovery in 1981, HIV-1 has led to the deaths of more than 33 million people 
worldwide. (UNAIDS) Current therapeutic efforts focus on reverse transcriptase and protease 
inhibitors. However, these methods do nothing to prevent HIV-1 infection and can only slow the 
progression of the disease. The chronic nature of HIV-1 implies that therapies are administered 
for life; therefore, selection of therapeutics is based not only on their efficacy but on their 
toxicological profile as well. (Blas-Garcia, et al) The emergence of drug-resistant strains of HIV-
1 has generated the need for more effective and less toxic anti-HIV agents.  In addition, the high 
mutation rate of HIV-1 prevents the production of an effect vaccine. HIV-1’s high infectivity, 
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lethality and aggressive rate of mutation have made potential anti-HIV	  agents a priority research 
subject. (Schader, Wainberg) 
Because of their integral part in the mechanism of HIV-1 infection, gp120 and gp41 are 
highly conserved in all virulent HIV-1 strains. Consequently, these glycoproteins are of interest in 
developing anti-HIV agents, particularly those that prevent further or initial infection. In recent 
years, cyanobacteria have cultivated a high level of interest as a potential new source of bioactive 
and novel secondary metabolites for use as anti-viral agents.  
Scytovirin, a potent anti-HIV-1 protein was originally isolated from aqueous extracts of the 
cyanobacterium Scytonema varium. Scytovirin has a molecular mass of 9713 Da, contains five 
intrachain disulfide bonds within two domains and one inter-domain disulfide bond. Scytovirin 
binds to the HIV-1 proteins gp120, gp41, and gp160 but not to the cellular receptor CD4. (Xiong, 
et al) Low nanomolar concentrations of purified Scytovirin inactivate laboratory strains of HIV-1 
by selective interactions between Scytovirin and the high mannose oligosaccharide-bearing 
glycoproteins gp120, gp41 and gp160. 
 
 
Figure 1.3: Aligned amino acid sequences of the two domains of Scytovirin. Starred amino acids indicate a conserved 
site. Disulfide bridges are indicated by solid lines above the sequence. Reprinted with permission from Dr. Robert 
McFeeters (personal correspondence). 
	  
The two domain sequences of Scytovirin show strong internal sequence duplication. 36 
residues (75%) are directly homologous and 3 residues (6%) represent conservative amino acid 
changes. (Bokesch, et al) Folding of the amino acid chain clusters aromatic residues in both 
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binding sites, suggesting an importance to retain aromatic chemistry when substituting amino 
acids during site-directed mutagenesis. (McFeeters, et al) As these sequences correspond to the 
binding sites of Scytovirin, it was postulated that both domains were equally important in anti-
HIV activity. Research by Liu, et al has indicated this to be true. Because each domain shows 
approximately equal anti-HIV activity, we decided to attempt to increase the activity of 
Scytovirin by engineering a Scytovirin protein derivative that contained a third domain. The 
second domain was selected to be engineered onto the wild-type Scytovirin protein to increase the 
binding affinity and anti-HIV activity of Scytovirin in the hopes of creating a new, less harmful, 
anti-HIV drug.  
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II. DESIGN AND SYNTHETIC APPROACHES TOWARDS THE DEVELOPMENT OF 
SD1-SD2-SD2 PROTEINS 
 Scytovirin, a protein isolated from the cyanobacterium Scytonema varium, is a high 
mannose-binding lectin that shows potent anti-viral activity. Scytovirin inhibits HIV replication 
with half maximal effective concentrations (EC50) in the low nanomolar ranges. (Sato, et al) 
Scytovirin also acts as a potent HIV-1 entry inhibitor. The mechanism by which Scytovirin 
inhibits adsorption of HIV-1 is mediated by several carbohydrate moieties on the virus surface, 
gp120, gp160, and gp41. Scytovirin specifically interacts with oligosaccharides containing α1-2, 
α1-6 trisaccharide units. Scytovirin is of particular interest as a prophylactic viral inhibitor 
because it does not bind to the human cellular receptor, CD4 (Xiong, et al)  
 Due to this potent anti-HIV activity, efforts to increase the binding affinity of Scytovirin 
have been widespread. Scytovirin is a 95 amino acid, straight chain protein with 10 cysteine 
residues that form 5 intrachain disulfide bonds. Wild-type Scytovirin has a molecular mass of 
9713 Da and folds into a dimeric structure of two domains, which represent its active form. The 
first comprises amino acids 1-48 and the second stretches from amino acids 49-95.  The disulfide 
bonds are integral in composing these two domains and by extension, the active sites of 
Scytovirin. Each cysteine residue must find its corresponding partner and create a di-sulfide bond 
in order to generate properly folded protein. The bonds form by the C20-C26 and C32-C38 
disulfides correspond closely to those defined by the C68-C74 and C80-C86 disulfide bonds in 
the second domain of Scytovirin. (Bokesch, et al) There is also a disulfide bond linkage between 
the 7th residue in the first domain, and the 55th residue in the second domain, which effectively 
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links the two domains and contributes to the 3D structure of the protein. The two domains share 
more in common than just the placement of the disulfide bridges within them. 
Scytovirin has a high level of sequence duplication: when residues 1-48 and 49-95 are 
aligned, 75% of the residues are identical and 6% make up conservative amino acid changes 
(Xiong, et al) NMR analysis of Scytovirin reveals that the two domains of the protein have strong 
symmetry.  
 
 
 
The two domains cluster aromatic residues in both sites, suggesting a binding mechanism similar 
to other known hevein-like carbohydrate-binding proteins. There are three aromatic residues in 
each domain (SD1, Y6, W8, F37; and SD2, Y54, W56, F85), and with the exception of F85 in 
SD2, all of the aromatic residues of Scytovirin are clustered near the binding sites. Mutation of 
these residues to non-aromatic species destroys the antiviral activity of Scytovirin (McFeeters, et 
al) However, the carbohydrate moieties recognized by Scytovirin are significantly different from 
hevein-binding carbohydrates. (McFeeters, et al) 
Previous experiments by Yinan Liu and affiliates have determined that the activity of 
Scytovirin and its relatives is significantly affected by the number of carbohydrate binding 
domains present, rather than their identity. (Liu, et al) However, other experiments by McFeeters 
and Xiong indicate that this might not be the exact case. ELISA experiments were performed to 
compare the binding ability to gp120 and gp41 of Scytovirin-derived peptides to Scytovirin. 
Figure 2.1 Amino acid sequence of Scytovirin with domain 1 (1-48) aligned with domain 2 (49-95). Disulfide 
brides are indicated by a solid line above the sequence. Identical amino acids are designated by =. Conserved 
sites are represented by *. Reprinted with permission from Dr. Robert McFeeters (personal correspondence).  
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The results showed that domain 1 of Scytovirin (SD1) appears to have gp120 and gp41 binding 
ability similar to intact Scytovirin. In contrast, domain 2 (SD2) has 57% reduced gp120 binding 
ability and approximately 44% reduced affinity to gp41. However, intact, wild-type Scytovirin 
demonstrates a several fold increase in binding affinity compared separately to either one of its 
domains. (Xiong, et al) Working with this knowledge in mind, we sought to increase the binding 
affinity and consequently the anti-HIV activity of Scytovirin by engineering a Scytovirin 
derivative with an extra carbohydrate-binding domain. As the second domain of wild-type 
Scytovirin was already equipped to be attached to a previous domain, duplication of this domain 
and subsequent incorporation onto the end of native Scytovirin protein was undertaken to 
potentially increase its anti-HIV activity. 
 
 
 
The project utilized a pET-32a vector to develop the mutant Scytovirin derivative 
sequences of SD2C55S. Synthetic sequences for wild-type Scytovirin, SC2, and the first domain, 
Figure 2.2 Surface representation of Scytovirin (SD1 pink, SD2 light blue) colored to show residues 
having largest change in chemical shift upon tetrasaccharide binding (SD1 red, SD2 blue). Reprinted 
with permission from Dr. Robert McFeeters (personal correspondence).  
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SD1, were assembled using a pET42b vector. Sequences for both domains were synthesized 
independently in pET32a vectors and linked together again via gene splicing. Recognizing the 
difficulty in generating a properly folded protein due to the high-interaction of multiple cysteines, 
the 55th residue, a cysteine, was replaced by serine using site-directed mutagenesis in the second 
domain of Scytovirin. This change was introduced to insure that the chemistry between the 
neighboring residues was retained as serine has the same relative size, shape, and chemical 
properties as cysteine without the possibility of generating errant disulfide bonds within the 
mutant protein. Following this change, the mutant protein was designated as SD1-SD2-SD2C55S 
to denote this mutation.    
 Inclusion of a BamHI site to the N-terminus of SD2C55S was accomplished by site-
directed mutagenesis. A thioredoxine sequence was fused to the N-terminus of SD2C55S to 
facilitate disulfide bond formation. (Stewart, et al)  Additionally, the KpnI digestion site was 
removed from the pET32a vector to facilitate separation of the construct from its fusion protein 
during purification. The C-terminal of SD2C55S included an XhoI restriction enzyme digestion 
site. Digestion of this vector by BamHI and XhoI produced the SD2C55S sequence, which was 
ligated to the synthetic gene construct for wild-type Scytovirin.  
 Three different linkers were designed to attach the synthetic, second domain of 
Scytovirin onto the wild-type, double-domained protein during PCR. Each linker derivative was 
synthesized and separated from incomplete or mutated sequences by electrophoresis. Bands of 
200bp were excised and purified by DNA extraction. Sequencing was used to determine the 
integrity of the DNA construct. Once extracted, each linker was digested using BamHI and XhoI 
restriction enzymes. Following digestion, the wild-type, long and short linkers were separately 
ligated to the BamHI and XhoI digested SD2C55S sequence to create three versions of SD2C55S. 
Each SD2C55S + linker sequence was separated from partially digested pieces of mutated 
sequences by electrophoresis, then extracted and purified.  
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 Wild Type linker Sequence 
T GCG ↓GAT CCG GGT TCT CGT AAA CCG GAC CCG GGG CCC AAA GGT CCG ACC  
   A           D     P      G     S      R      K      P     D       P       G     P       K      G      P     T 
TAC TGC TG 
  Y       C 
Short Linker Sequence 
T GCG ↓GAT CCG GGC GGT TCT TCT GGT CCC AAA GGT CCG ACC TAC TGC T 
    A          D      P     G      G      S     S      G      P      K      G      P     T       Y     C 
Long Linker Sequence 
T GCG ↓GAT CCG GGT TCT AGC GGT GGC TCT AGC GGC  TCT TCT GGT CCC AAA  
   A           D     P      G      S     S       G      G      S     S       G        S     S     G      P      K 
GGT CCG ACC TAC TGC T 
 G          P         T         Y          C    
  
 
Each of these versions of SD2C55S was then ligated to the end of the second domain of 
wild-type Scytovirin, SC2, using slow ligation. A histidine tag sequence was introduced onto the 
ends of all three versions of SD1-SD2-SD2 to aid in later protein purification. The SD1-SD2-
SD2C55S constructs were digested with the restriction enzymes BamHI and XhoI, and separated 
from incomplete sequences using electrophoresis. The constructs were then extracted, purified, 
and ligated together into the final, previously BamHI and XhoI digested plasmid. The resulting 
Figure 2.3 Nucleotide sequences for the synthetic linkers and the encoded amino acid sequences.  
Reprinted with permission from Dr. Robert McFeeters (personal correspondence).  
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complete DNA sequences for SD1-SD2-SD2C55S were amplified by PCR, and then purified 
using the GeneJet PCR Purification Kit.  
 The purified DNA products for all three versions of SD1-SD2-SD2 were transformed into 
JM109 competent cells to amplify DNA product and to test the transforming capabilities. SD1-
SD2-SD2C55S short linker and SD1-SD2-SD2C55S wild-type linker were transformed 
successfully. The SD1-SD2-SD2C55S long linker sequence has not yet been successfully 
transformed. Work on this version of SD1-SD2-SD2 has been halted. Once SD1-SD2-SD2C55S 
short and wild-type linker sequences were transformed into JM109 cells the transformed cell 
cultures were miniprepped to extract the recombinant plasmids. Both SD1-SD2-SD2C55S 
sequences were double digested using BamHI and XhoI and separated using electrophoresis to 
determine proper ligation.  All three versions of SD1-SD2-SD2C55S were sent for sequencing. 
All three DNA sequences were determined to be as had been designed. It is still not clear why 
SD1-SD2-SD2C55S long linker will not transform into competent E. coli cells.    
 
 
1         2        3        4         5       6         7          8         9 
Figure 2.4 SDS-PAGE gel depicting expression of SD1-SD2-SD2 WT and SD1-SD2-SD2 SL. 1) Protein ladder 
2) SD1-SD2-SD2 WT uninduced 3) SD1-SD2-SD2 WT induced 4) SD1-SD2-SD2 SL uninduced 5) SD1-SD2-
SD2 SL induced. Lanes 6-9 represent wild-type Scytovirin protein expression.  
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Small-scale expressions of both SD1-SD2-SD2 short linker and SD1-SD2-SD2 wild-type linker 
were carried out in LB, M9, Soc, and Spectra 9 with Origami competent cells at 37 °C. Previous 
experiments by McFeeters, et al have determined that Origami competent cells express and fold 
Scytovirin better than other E. coli strains. 
 Using this knowledge, experimentation with expression parameters was carried out to 
determine the best way to express large amounts of soluble SD1-SD2-SD2. Through these small-
scale expressions, it was determined that Origami cells expressed more soluble protein in LB than 
in any other media. Soluble protein yields are quite high using Origami cells, however properly 
folded protein yields were not optimal. Steps were taken to determine the optimal parameters to 
increase proper folding of SD1-SD2-SD2 mutants.  
 Many large-scale expressions of SD1-SD2-SD2 short and wild-type linkers were 
performed. Two separate media were utilized, LB and M9. Inoculated cultures of transformed 
cells were grown at 37 °C until time of induction, at which point they were grown at 18 °C, 30 °C, 
and 37 °C in both media. Cultures were induced at an OD590 of approximately 0.6, and harvested 
approximately 4 hours after this time. Harvested protein was purified by FPLC, a restriction 
digest to remove the thioredoxine tag, two buffer exchanges, and reverse phase HPLC.  
 Protein expressed at 18 °C produced the worst yields; protein that was expressed at 30 °C 
seemed to demonstrate improved yields of properly folded protein.  Purified protein samples were 
then condensed to a minimal volume using high-speed centrifugation to determine the overall 
structure using 2D NOESY NMR. 
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Figure 2.5 2D NOESY NMR of SD1-SD2-SD2 wild-type linker aligned against Scytovirin. Scytovirin is 
depicted in red, SD1-SD2-SD2 wild-type linker is depicted in blue and green represents the negative 
spectrum of SD1-SD2-SD2 wild-type linker. Reprinted with permission from Dr. Robert McFeeters 
(personal correspondence). 
16	  
	  
III. CONCLUSIONS AND FUTURE PERSPECTIVES 
 Scytovirin, a novel anti-HIV protein isolated from the cyanobacteria Scytonema varium, 
is a small, 95 amino acid, straight chain protein with a high incidence of internal sequence 
duplication and 5 intrachain disulfide bonds. Scytovirin demonstrates high anti-viral activity, as 
well as anti-HIV activity in the nanomolar concentrations. Additionally, Scytovirin binds 
specifically to gp120, gp41 and gp160 of HIV-1, the proteins essential to viral adsorption but not 
to the CD4 receptor. This high-mannose oligosaccharide binding specificity offers a new, safe 
approach to inhibiting HIV-1 infection. As a result, Scytovirin has garnered interest as a possible 
therapeutic approach to controlling and diminishing HIV levels in affected individuals.   
 Efforts were made to increase the binding affinity, and therefore the anti-HIV activity, of 
Scytovirin through protein engineering. Because of the high sequence duplication of the two 
domains of Scytovirin, it was postulated that both have similar binding affinities for 
glycoproteins on HIV-1. In fact, there is almost no discernible difference in the binding affinities 
of the domains of Scytovirin (Liu, et al). Increased affinity of Scytovirin is achieved by binding to 
larger glycoproteins such as gp160, gp41 and gp120 that deliver carbohydrates to both Scytovirin 
domains. (McFeeters, et al) The high anti-HIV activity of Scytovirin is likely due to this 
multivalency. Because interaction with both domains increases the activity of Scytovirin, steps 
were taken to engineer the second domain of Scytovirin onto the end of the wild-type protein in 
order to attempt to greatly increase its anti-HV activity. 
 A pET 32 vector was utilized to clone and express the Scytovirin mutants. Three versions 
of the DNA sequence coding for the proteins SD1-SD2-SD2 short linker, SD1-SD2-SD2 wild-
type linker and SD1-SD2-SD2 long linker were synthesized. A thioredoxine tag was introduced at 
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an enterokinase restriction site between the Scytovirin peptide sequences and their fusion partner 
to enhance disulfide bond formation and proper folding during protein expression. (Stewart, et al 
and Stoll, et al) Several key mutations of cysteine to serine were induced in the recombinant, 
second domain of SVN to reduce improper disulfide bond formation while maintaining similar 
amino acid chemistry. DNA sequences for SD1, SD2, and SD2C55S were cloned in JM109 E. 
coli cells. Extracted DNA was digested, purified, and ligated to create three recombinant plasmids 
for the three Scytovirin mutants. The integrity of the plasmids was confirmed by DNA 
sequencing.  
 Successful expression of SD1-SD2-SD2 wild-type linker and SD1-SD2-SD2 short linker 
was achieved in Origami cells. Once expression of soluble protein was achieved, efforts were 
undertaken to increasing the yields of properly folded protein. Multiple parameters were changed 
to measure the impact on yields of properly folded protein such as temperature and culture 
medium. It was found that LB media creates a higher yield of protein, as does growth and 
induction at 37 °C. However, when SD1-SD2-SD2 wild-type linker was compared to Scytovirin 
using 2D heteronuclear NOESY NMR it was clear that proper folding of the mutant protein was 
not obtained.  
 Screening of the SD1-SD2-SD2 mutants has been deferred until proper folding is 
attained. Many of the folding problems stem from the multiple, sequential disulfide bridges in 
Scytovirin as well as the interdomain sulfide bridge that is largely responsible for the overall 
structure of Scytovirin and, consequently, its antiviral activity. Because of this, additional 
research is required to induce more mutations in the DNA sequence to facilitate proper folding. 
Additional cell lines will be screened for their expression and possible roles in folding of 
Scytovirin. Once large quantities of properly folded SD1-SD2-SD2 mutants have been expressed 
and purified, they will be screened for increased anti-HIV activity to improve the HIV drug 
cocktail and potentially bring us closer to a cure.  
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Figure 3.1 2D NOESY NMR of SD1-SD2-SD2 wild-type linker aligned against Scytovirin. Scytovirin 
is depicted in red, SD1-SD2-SD2 wild-type linker is depicted in blue and green represents the negative 
spectrum of SD1-SD2-SD2 wild-type linker. Reprinted with permission from Dr. Robert McFeeters 
(personal correspondence). 
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IV. MATERIALS AND METHODS 
General Methods: 
 All reactions involving live Escherichia coli were carried out in a sterile flame hood 
using flame-dried glassware.  All transformations for the expression of SD1-SD2-SD2 used the 
Origami cell line unless otherwise noted. All transformations for the purification of DNA used 
the JM109 cell line unless otherwise noted. All reactions allowed to proceed ‘overnight’ 
progressed for 12 hours or more unless otherwise noted. All commercially available starting 
materials and reagents were purchased at the highest commercial quality and used without further 
purification unless otherwise noted. All PCR procedures were run on the program ‘Mary Sing’ 
unless otherwise noted. All chemicals were purchased from Sigma, Aldridge, Promega or 
Fermentas chemicals. All primers used were purchased from ING laboratories in Huntsville, 
Alabama. The Dr.’s Robert and Hanna McFeeters developed all procedures used unless otherwise 
noted. 
General Procedure for Standard PCR: 
A mixture of 5 µL tag10x buffer, 5 µL 2 mM dNTP, 1.25 µL Primer 41, 1.25 µL Primer 49, 4 µL 
25 mM MCl2, 2 µL purified DNA, 1 µL taq polymerase and 30.5 µL dH2O was mixed on ice 
before undergoing PCR.  
General Procedure for Emerald Amp PCR: 
25 µL emerald master mix, 2 µL purified DNA, 1 µL Primer 41, 1 µL Primer 49 and 21 µL dH2O. 
Run on program ‘Mary Sing’. 
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General PCR Purification Procedure: 
47 µL of binding buffer was added to 47 µL of the PCR mixture and mixed thoroughly in a 
microcentrifuge tube at 14,000 rpms for 30 seconds. 47 µL of 100% isopropanol was added to the 
solution per 500 base pairs of DNA. Solution was transferred to the GeneJet purification column. 
Column was centrifuged for 30-60 seconds at 14,00 rpms. Flow-through was discarded. 700 µL 
of the wash buffer was added. Mixture was centrifuged for another minute. The flow-through was 
discarded. The column was then centrifuged for another minute to maximize purification of DNA 
product. GeneJet column was placed into sterile 1.5 mL microfuge tube. 25 µL of ddH2O was 
added to the column. Mixture allowed to incubate at 25 °C for 1 minute. Tube was centrifuged for 
1 minute. Another 25 µL of ddH2O was added to the tube and allowed to incubate for 1 minute at 
25 °C. Tube was centrifuged for 1 minute; flow-through was saved.  
General Procedure for Transformation of SD1-SD2-SD2 vector for Expression: 
5 µL of desired DNA was added to 50 µL of thawed competent cells in a plastic Falcon tube, then 
gently swirled. Tubes were allowed to sit on ice for 45 minutes. Tubes were then shocked for 1 
minute and 15 seconds in a 42 °C water bath. Tubes were placed back onto ice for an additional 2 
minutes. 0.5 L of LB was added  to each of the tubes and gently mixed. Tubes were placed in and 
incubator at 37 °C, 250 rpms for 1 hour. 200 µL of cell/LB mixture were plated to prepped 
carbenicillin plates in a sterile flame hood. Plates were incubated overnight at 37 °C. 1 mL of LB 
was added to original tubes along with 1.1 µL of carbenicillin. Tubes were placed in the shaker at 
250 rpms and 37 °C overnight.  
Carbenicillin Plate Preparation: 
12.23g of LB agar mixed with 300 mL ddH2O in a flame-sterilized beaker. Mixture autoclaved on 
the liquid setting. After autoclaving, 300 µL of carbenicillin was added when mixture reached 25 
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°C. Plates were poured in sterile flame hood and allowed to harden in the flame hood until 
transferred to the -20 °C refrigerator for storage.  
Before transformed competent cells were spread onto agar plates, all plates were thawed in sterile 
flame hood and each coated with 100 µL of  a 20 µL chloramphenicol to 80 µL LB solution. 
Plates were allowed to dry fully in sterile flame hood before plating with competent cells.  
Site-directed Mutagenesis Procedure: 
100 µL of ddH2O was added to designed, dehydrated primers. Primers were vortexed to mix 
thoroughly. 5 µL of 10x reaction buffer, 5 µL of dsDNA template (SD1 pET42b), 1.25 µL of 
oligonucleotide control primer #1, 1.25 µL of oligonucleotide control primer # 2, 1 µL of dNTP 
mix, 1.5 µL of QuikSolution reagent, and 34 µL of ddH2O were combined in mini PCR tubes on 
ice, vortexed to mix. Then 1 µL of QuikChange lightning enzyme was added to the reaction 
mixture, vortexed and gently spun down. Run on program “Morgan” in PCR machine. 
Transformation of Purified PCR Product General Procedure: 
A mixture of 1 µL of p-prime cloning vector, 4 µL of purified PCR product, and 5 µL of ligation 
master mix in a microcentrifuge tube, thoroughly mixed at 14,00 rpms for 1 minute. Mixture was 
then incubated at 4 °C for 30 minutes. 7 µL of the mixture was transformed into 70 µL of JM109 
E. coli competent cells according to the general transformation procedure. Carbenicillin plates 
were prepared with 100 µL of 100 mM IPTG plus 20 µL of 50 mg/mL X-Gal. 300 µL of cell and 
LB broth mixture was plated. Incubated overnight at 37 °C. White colonies were selected for 
DNA purification.  
Cloned DNA purification general procedure: 
One E. coli colony of medium size and significant distance from neighboring colonies was 
selected per plate. Colonies were extracted in a sterile flame-hood and transferred to a mixture of 
3 mL of LB broth and 3 µL carbenicillin in a 50 mL glass vial. Tubes were placed in the 
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incubator over night at 37 °C and 250 rpms. 1.5 mL from each tube was transferred to 1.5 ML 
centrifuge tubes. Mixture was centrifuged at 14,000 rpms for 5 minutes. Supernatant was 
discarded and procedure was repeated until all of the bacteria from each tube had formed pellets. 
Pelleted cells were resuspended with 250 µL of Resuspension solution. 250 µL of Lysis solution 
and 350 µL of Neutralization solution were added to each centrifuge tube and mixed thoroughly 
by inversion. Tubes were centrifuged for 5 minutes at 14,000 rpms. The supernatant from each 
tube was loaded into a GeneJet spin column. Supernatant was centrifuged for 1 minute at 14,00 
rpms and the flow-through was discarded. 500 µL of Wash solution was added to each GeneJet 
spin column. The column was centrifuged for 1 minute and the flow-through was discarded. 
Wash and discarding of the flow-through was repeated. Empty column was centrifuged for one 
additional minute to maximize separation of DNA product from added solutions. The spin 
column was then transferred to a new microcentrifuge tube. 30 µL of ddH2O was added to the 
column. Column was incubated at 25 °C for 2 minutes. Column was centrifuged inside centrifuge 
tube at 14,000 rpms for 2 minutes. An additional 30 µL of ddH2O was added to the column and 
the incubation and centrifugation was repeated. The flow-through was collected. DNA 
concentration of the purified product was checked using UV spectroscopy.  
Restriction Digest of synthesized DNA product: 
A mixture of 10 µL of purified PCR product, 2 µ of 10x buffer, 6 µL of ddH2O, 1 µL BamHI 
enzyme, and 1 µL of XhoI enzyme was mixed in a centrifuge tube and allowed to incubate at 37 
°C for 60 minutes. Digested DNA was then run through a DNA agarose gel to separate DNA 
sequences by size. Desired DNA pieces were then purified to be used in later procedures.  
DpnI Digest of Site-directed Mutagenesis Amplification Products: 
2 µL of the DpnI restriction were added to each amplification reaction. Reaction was mixed 
thoroughly and spun down briefly. Mixture was incubated at 37 °C for 30 minutes. Digested 
DNA was immediately transformed in XL-10 gold E. coli competent cells. 2 µL of DNA, 2 µL of 
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the β-ME mix and 45 µL of XL-10 gold cells were combined on ice. Mixture was allowed to 
incubate on ice for 30 minutes. Competent cell mixture was heat shocked for 30 seconds at 42 °C, 
placed back on ice for another 2 minutes. 0.5 mL of preheated NZY+ broth was added to each 
transformation tube. Tubes were placed in the incubator for 1 hour at 37 °C and 250 rpms. 200 µL 
of competent cells were plated on Kanamycin plates and incubated at 37 °C overnight. Colonies 
containing the desired plasmids appear blue on agar plates containing 80 µg/mL X-Gal and 20 
mM IPTG. 
DNA Extraction and Purification Procedure: 
Excise the desired bands of DNA from the stained agarose DNA gel with a razor blade. 
Determine the approximate volume of the DNA piece by weighing, then transfer the piece to a 
sterile 1.5 mL centrifuge tube. If the piece is larger than 0.40g, a larger centrifuge tube is 
necessary. 3 equivalents of Binding solution was added per 1 equivalent of DNA gel. The tube 
was then placed in a 55 °C water bath and incubated for 5 to 10 minutes or until the DNA gel had 
liquefied. The tube was briefly centrifuged every 3 minutes of incubation. Once liquefied, add a 
volume of TE buffer to bring the total volume to 100 µL. 2 µL of silica powder suspension was 
added per 1 µL of DNA and mixture was incubated for 5 minutes at 55 °C. Silica powder 
suspension was resuspended to produce a homogenous suspension by rigorous mixing every 1 to 
2 minutes while incubating. The silica powder and DNA mixture was centrifuged for 5 seconds at 
14,000 rpms. The supernatant was removed and set to the side. 500 µL of ice cold wash buffer 
was added to resuspend the pellet. Mixture was then centrifuged for 5 seconds at 14,000 rpms and 
the supernatant was discarded. Wash procedure was repeated 3 more times. The washed silica and 
DNA pellet was then resuspended with 500 µL of ddH2O. Tube was incubated at 55 °C for 5 
minutes. Mixture was centrifuged for 30 seconds at 14,000 rpms. Supernatant containing purified 
DNA was then carefully extracted and placed into sterile centrifuge tube. 
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General Slow-Ligation Procedure: 
3 µL of previously digested SC2 Bam HI kpnKO, 12 µL of previously digested SD2C55S linker, 
2 µL of buffer, 3 µL of dH2O, and 1 µL ligase were combined in a sterile microcentrifuge tube 
and allowed to incubate at 25 °C for 1 hour. 10 µL of ligation product was transformed into 120 
µL of JM109 cells and plated according to the general transformation procedure for JM109 cells.  
Procedure for SDS-PAGE 12% Protein Resolving Gel: 
2.4 mL of H2O, 1.1 mL of 2M Tris-HCl, pH 8.8, 37.5 µL of 20% SDS, 2.4 mL of 
Acrylamide/Bis-acrylamide 30%/0.8% (w/v), 40 µL of 10% ammonium persulfate (w/v), and 14 
µL TEMED were combined in a 50 mL glass beaker by gentle pipetting. Solution was poured 
into protein gel mold, topped with distilled H2O and allowed to polymerize.  
Procedure for SDS-PAGE 4% Stacking Gel: 
1.8 mL of H2O, 0.75 mL of 0.5M Tris-HCl pH 6.8, 15 µL of 20% (w/v) SDS, 0.40 mL of 
Acrylamide/Bis-acrylamide 30%/0.8% (w/v), 30 µL of 10% (w/v) ammonium persulfate, and 6 
µL of TEMED were combined in a sterile, 10 mL glass beaker. Water over polymerized resolving 
gel was removed, and the stacking gel mixture was pipetted on top of the polymerized resolving 
gel. Stacking gel was allowed to polymerize. 
Protein Gel Silver Stain Procedure: 
All steps were performed in a single, clean plastic staining tray with constant, gentle shaking. 
Protein gel was washed 2 times with ddH2O for 5 minutes. Protein gel was fixed twice for 15 
minutes in 30% etOH: 10% acetic acid solution. Protein gel was washed twice for 5 minutes in 
10% etOH, then twice for 5 minutes in ddH2O. Sensitizer Working solution was prepared by 
mixing 50 µL sensitizer with 25 mL H2O. Protein gel was sensitized for 1 minute, then washed 
twice for 1 minute each in ddH2O. Protein gel was stained for 30 minutes with silver stain. Gel 
was washed twice for 20 seconds each with ddH2O, then gel was developed for 2 to 3 minutes or 
until bands began to appear. Development was quenched with 5% acetic acid for 10 minutes.  
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M9 Media: 
3.4 g Na2HPO4, 1.5 g KH2PO4, 0.25 g NaCl, 1.0 g dextrose, 0.5 g NH4Cl, 5 mL divalent, 1 mL 
vitamin B, 5 µL trace elements were combined and diluted with 500 mL of ddH2O. Mixture was 
sterile filtered and stored until use.  
Large-Scale Expression of Protein Product in Spectra 9 N15 from plates: 
Colonies of previously transformed Origami cells were washed from plates into 500 mL of 
Spectra 9 (N15) media with 250 µL of carbenicillin. Reaction mixture was incubated at 37 °C at 
250 rpms and bacterial growth was measured periodically using optical density. Cells were 
induced with 500 µL of IPTG and allowed to continue expression for 5 hours. Cell mixture was 
then spun down on a JLA-16 250 rotor at 7,000 rpms until the entire mixture was condensed to 
pelleted cells. Supernatant was discarded and the cell pellet was stored at -80 °C for at least 6 
hours before beginning lysis.  
General Protein Purification Procedure: 
Pellet was transferred from -80 °C into a 50 mL conical tube on ice.  20 mL of 50 mM NaP 
buffer, pH 6.8 was added to the pellet and resuspended carefully to reduce bubble formation. 15 
mg of lysozyme, 200 µL of 1M MgCl2, and 20 µL of DNAse were added. Mixture was allowed to 
incubate at 25 °C for 30 minutes. Mixture was sonicated at 50% output for 16 minutes, alternating 
1 minute of sonication and 1 minute on ice. Centrifuge at 20,000 rpms in JA25.50 rotor for 30 
minutes at 4 °C. Immediately separate the supernatant from the pellet and store at 4 °C until ready 
to be processed by FPLC.  
General Procedure for FPLC: 
Run using the absorbance mode at 0.05. Load filtered supernatant at 2 mL/min onto a 5 mL 
“HisTrap FF” (GE Healthcare, Cat. # 17-5255-01) nickel affinity column that has been 
equilibrated in Buffer A and collect 2 mL fractions. Save the flow through. Manually switch to 
40% Buffer B at an A280nm of about 0.5 . Wash the column at 40% Buffer B until the  A280nm 
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stabilizes and starts to slightly go up (approximately 10 mLs of total elution at 40% BufferB). 
Manually switch to 100% Buffer B. Approximately 2 to 3 fractions later Scytovirin derivatives 
should elute as a symmetrical peak with an A280nm between 2000-2500 on an AKTA FPLC. Pool 
relevant fractions and dialyze in a 3 to 12 mL 10 kDa molecular weight cutoff cassette with 50 µL 
of thrombin versus 2 L of 20 mM Tris-HCl, pH 7.6 with 50 mM NaCl for 4 hours at 4 °C. 
Transfer solution to a 2059 tube and add 1M MgCl2 to a final concentration of 2 mM. Add 1.5 to 
2 µL of rEK (Novagen, Cat. # 69066,  ~ 2.1 U/µl) per mL  of Scytovirin and incubate overnight at 
32 °C.  
Reverse Phase HPLC Purification Procedure: 
1 µL of PMSF was added per 1 mL of Scytovirin solution. Centrifuge cut Scytovirin derivative at 
20,000 rpms in a microfuge for 20 minutes. Load and inject 5 mL aliquots onto a C18 column 
(BioRad, HiPore RP318, 10mm X 250mm, Cat. # 155-9111) equilibrated in Buffer A. Run 
“sc2_improved” method: 0-24% Buffer B from 0 to 41 minutes, 24-57% Buffer B from 41 to 50 
minutes, 57-90% Buffer B from 50 to 59 minutes, 90-0% Buffer B from 59 to 70 minutes. Collect 
1 mL fractions. Properly folded Scytovirin derivatives elute at a retention time of 40 to 41 
minutes. A smaller peak just after this elution at 41 to 43 minutes is misfolded protein. Pool 
relevant samples and equilibrate C18 column in methanol until next use. Freeze pooled samples 
in liquid nitrogen and lyophilize for 48 hours. Weigh dry weight of Scytovirin derivative. Store 
Scytovirin desiccated in foil at room temperature.  
Post-HPLC Dialysis for NMR Preparation: 
Pool relevant samples. 3.1 mL of 0.05% TFA buffer was added to pooled samples. 9.3 mL of 
Scytovirin NMR buffer was added to the pooled samples. Mixture was pipetted into dialysis 
tubing. Mixture was dialyzed versus 1 L of NMR buffer at 4 °C, overnight.  
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Scytovirin NMR Buffer: 
4.264g of MES powder, 222 µL of 0.45M EDTA stock and 10 µL of 1M NaN3 stock were 
combined and diluted with 1 L of ddH2O. Final concentrations were 20 mM MES, pH 5.5, 100 
µM EDTA, 10 µM NaNs.  
Competent Origami Cell Procedure: 
Inoculate 50 mL LB with a single colony of E. coli. Grow overnight at 37 °C and 250 rpms. 
Inoculate 4 mL culture into 400 mL LB in a sterile, 2-liter flask. Grow at 37 °C, 250 rpms, to an 
OD590 of 0.375. aliquot culture into 8 50-mL prechilled sterile polypropolene tubes and leave on 
ice for 5 to 10 minutes. Centrifuge tubes for 7 minutes at 16,000 x g at 4 °C. Discard supernatant 
and gently resuspend pellet in 10 mL ice-cold CaCl2 solution. Centrifuge 5 minutes at 1,100 x g 
at 4 °C. Discard supernatant and resuspend in 10 mL CaCl2. Keep on ice for 30 minutes. 
Centrifuge for 5 minutes at 1,100 x g at 4 °C. Discard supernatant and resuspend pellet in 2 mL 
CaCl2. Dispense 250 µL aliquots into prechilled, sterile polypropylene tubes and freeze 
immediately at -80 °C.  
1% DNA Agarose Gel: 
35 mL TAE 1x buffer, 0.35g agarose gel, and 12 µL ethidium bromide were combined in a 
sterile, 50 mL plastic beaker and microwaved on high for 45 seconds. Mixture was poured into 
DNA gel mold, comb inserted and allowed to set. Polymerized gel was placed in electrophoresis 
cell. 1x TAE buffer was used to cover the gel. All gels run at 120 mA.  
50 mM NaP, 300 mM NaCl pH 7.5: 
100 mL of 500 mM stock NaP, and 70 mL of 4.2 M NaCl filled to 1 liter with ddH2O, pH 
adjusted to 7.5. Stock used for making buffers for FPLC, 600 mL used for Buffer A without 
derivation and 400 mL used for Buffer B.  
Buffer for Removal of Imidazole from Scytovirin: 
40 mL of 1M Tris, and 24 mL of 4.2 M NaCl filled to 2 liters with ddH2O. pH adjusted to 7.6.  
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FPLC Buffer B: 
400 mL of 50 mM NaP 300 mM NaCl pH 7.5 was added to 4.085 g of Imidazole (fw = 68.08 g).  
LB Media: 
8.00 g of LB agar into a sterile, 600 mL glass beaker. ddH2O added to the 400 mL mark. Place on 
stirrer/hotplate until agar fully dissolves. Separate into sterile glass bottles and autoclave on the 
liquid setting.  
50 mg/mL X-Gal: 
0.05 g of X-Gal into 1 mL DMSO. 
NZY+ Broth: 
10 g of NZ amine (casein hyrdolysate), 5 g of yeast extract, 5 g of NaCl, and fill to 1 liter with 
ddH2O. Adjust pH to 7.5 using NaOH. Autoclave on the liquid setting. Before use add: 12.5 mL 
of 1M MgCl2, 12.5 mL of 1M MgSO4, 10 mL of a 2M filter-sterilized glucose solution and then 
filter sterilize.  
10x Reaction Buffer for QuikChange site-directed Mutagenesis: 
100 mM KCl, 100 mM (NH4)2SO4, 200 mM Tris-HCl (pH 8.8), 20 mM MgSO4, 1% Triton X-
100, 1 mg/mL nuclease-free bovine serum albumin (BSA). 
TE Buffer: 
10 mM Tris-HCl pH 7.5, 1 mM EDTA 
HPLC Buffer A: 
HPLC grade H2O that is 0.05% TFA. 
HPLC Buffer B: 
90% HPLC grade acetonitrile, 10% HPLC grade H2O solution that is 0.05% TFA.  
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